EN DE
Watch Senhwa Biosciences, Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Senhwa Biosciences, Inc. (6492) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Senhwa Biosciences, Inc. stock TWD 13.65, price TWD 28.65, that is 52.4% below the price, quality 48 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW

SB Senhwa Biosciences, Inc. logo Thin data Nov 16, 2026

Senhwa Biosciences, Inc.

6492 · TWO

Far too expensive (fair value 52% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Quality 48/100 
Expensive Growth (revenue 3y +2.3 %/yr in TWD) 
Fair value 13.65 TWD · Strongly overvalued 
Falling price (downtrend) 
Negative free cash flow 
Trails peers (2/7) 
Narrow moat 5/100
Thin data 
Estimate
Watch Senhwa Biosciences, Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

203.50 TWD 28.65 TWD Fair Value 13.65 TWD Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 28.65 TWD – 203.50 TWD · fair‑value band 10.24 TWD – 17.06 TWD · the 28.65 TWD price screens above the 13.65 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Senhwa Biosciences in your weekly email

Every Wednesday you see whether Senhwa Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Senhwa Biosciences, Inc. engages in the development of novel drugs and special active pharmaceutical ingredients.

Show moreShow less

The company offers novel drugs, a small-molecule drugs for treating cancers: G-quadruplex stabilizer Pidnarulex (CX5461) for the treatment of breast cancer and other homologous repair deficiency (HRD) or solid tumors from BRCA1/2 gene mutation; inhibitor of protein kinase CK2 (casein kinase II); and Silmitasertib (CX4945) for the treatment of cholangiocarcinoma, basal cell carcinoma, and medulloblastoma.

It also provides technical advice and consulting services. Senhwa Biosciences, Inc. is based in New Taipei City, Taiwan.

Stock analysis

Senhwa Biosciences, Inc. (6492) currently trades at 28.65 TWD, while our estimate is 13.65 TWD, 52% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 10.24 TWD (bear) to 17.06 TWD (bull), the price of 28.65 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Senhwa Biosciences, Inc. reported revenue of 1.1M TWD in FY2025 versus 550K TWD in FY2021, a compound +18.1%/yr. Reported net income was −265M TWD in FY2025.

Key figures

Market cap 3.4B TWD (≈ $102M) Micro · EPS (TTM) −3.22 TWD · Return on equity −39.0% · Return on assets (EBIT) −24.8% (5-year average) · Operating margin −35,328% · Revenue (TTM) 1.1M TWD · Revenue growth (YoY) −4.0% · Free cash flow −249M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (medium confidence).

What moves the price

The share trades about 56% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −52%, 6492 screens richer than that median.

Fair Value

Bear 10.24 TWD Fair Value 13.65 TWD Bull 17.06 TWD
Price 28.65 TWD · Downside -52.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 48/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 50
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 62
How calm the share price moves, does not count
Price momentum 8
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 80
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 10/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+7.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−62,966.5% (2021) → −26,005.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6492 screens overvalued: fair value 52% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Senhwa Biosciences, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 48 · Above median
Fair Value upside −52.8% · Bottom 25%
Profitability
Return on assets −32.3% · Below median
Growth and dividend
Revenue growth (quarter YoY) −4.0% · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.46× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 21

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs 6492
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs 6492
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs 6492
argenx SE ARGX $950.95 $908.40 −4% vs 6492
CSL Limited CSL A$199.55 A$186.49 −7% vs 6492
Moderna, Inc MRNA $215.27 $135.64 −37% vs 6492
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs 6492
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs 6492
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs 6492
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs 6492

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Senhwa Biosciences, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Senhwa Biosciences, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/6492

Frequently asked questions

Is Senhwa Biosciences, Inc. (6492) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 13.65 TWD versus a price of 28.65 TWD, about 52% lower (overvalued).
What is the fair value of 6492?
Our estimate for Senhwa Biosciences, Inc. is 13.65 TWD (as of Nov 16, 2026), built from audited fundamentals. The current price: 28.65 TWD.
What is the quality score of 6492?
Senhwa Biosciences, Inc. has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Senhwa Biosciences, Inc. (6492)?
Our calculated price target is the estimate of 13.65 TWD (as of Nov 16, 2026). Cautious scenario 10.24 TWD, optimistic scenario 17.06 TWD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Senhwa Biosciences, Inc. stock forecast for 2026?
Our estimate puts fair value at 13.65 TWD, about 52% lower versus a price of 28.65 TWD (overvalued). Cautious scenario 10.24 TWD, optimistic scenario 17.06 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Senhwa Biosciences, Inc. (6492)?
Senhwa Biosciences, Inc. reported trailing-twelve-month revenue of about 1.1M TWD (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Senhwa Biosciences, Inc. (6492)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Senhwa Biosciences, Inc. it is 13.65 TWD per share (as of Nov 16, 2026), against a price of 28.65 TWD.
Is Senhwa Biosciences, Inc. stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 6492 trades above its calculated fair value: price 28.65 TWD, fair value 13.65 TWD, a gap of about −52% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6492?
No. The price is what the market pays today (28.65 TWD); the fair value is what the company's own numbers justify (13.65 TWD). For Senhwa Biosciences, Inc. the two are 15.00 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Senhwa Biosciences, Inc. worth?
The market values Senhwa Biosciences, Inc. at about 3.4B TWD (market capitalisation, as of Nov 16, 2026). Per share that is 28.65 TWD; our models calculate a fair value of 13.65 TWD per share.
What do the bullish and bearish scenarios say about 6492?
Our models span a range for Senhwa Biosciences, Inc.: cautious scenario 10.24 TWD, base 13.65 TWD, optimistic 17.06 TWD per share (as of Nov 16, 2026, price 28.65 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Senhwa Biosciences, Inc. (6492)?
Balance-sheet figures for Senhwa Biosciences, Inc. (as of Nov 16, 2026): return on equity −39.0%. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 6492 from its 52-week high?
Senhwa Biosciences, Inc. trades at 28.65 TWD, about 56% below its 52-week high of 65.50 TWD and at the low of 28.65 TWD (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of 13.65 TWD is for.
Which stocks are comparable to Senhwa Biosciences, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Senhwa Biosciences, Inc. stock attractive at the current price?
The data as of Nov 16, 2026: price 28.65 TWD, calculated fair value 13.65 TWD (−52%), Quality Score 48/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Senhwa Biosciences, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Senhwa Biosciences, Inc. (6492)?
The closing price on Nov 17, 2026 was 28.65 TWD. Our estimate is 13.65 TWD, about 52% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Senhwa Biosciences, Inc. right now?
The price sits above even our optimistic bull case (17.06 TWD). The favourable scenario is already priced in. Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Senhwa Biosciences, Inc.

How large is the market capitalisation of Senhwa Biosciences, Inc. (6492)?
The market capitalisation of Senhwa Biosciences, Inc. is 3.4B TWD (≈ $102M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Senhwa Biosciences, Inc. (6492)?
Earnings per share at Senhwa Biosciences, Inc. are −3.22 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Senhwa Biosciences, Inc. (6492)?
The return on equity (ROE) of Senhwa Biosciences, Inc. is −39.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Senhwa Biosciences, Inc. (6492)?
On an EBIT basis the return on assets of Senhwa Biosciences, Inc. is −24.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Senhwa Biosciences, Inc. (6492)?
The operating margin of Senhwa Biosciences, Inc. is −35,328% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Senhwa Biosciences, Inc. (6492)?
Revenue at Senhwa Biosciences, Inc. is down 4.0% versus a year earlier (3y avg +2.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Senhwa Biosciences, Inc. (6492) generate?
The free cash flow of Senhwa Biosciences, Inc. is −249M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Senhwa Biosciences, Inc. in the live analysis

One click puts Senhwa Biosciences, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.